Categories AlphaGraphs, Earnings, Health Care
Infographic: A snapshot of Moderna’s (MRNA) Q1 2024 earnings results
Moderna, Inc. (NASDAQ: MRNA) reported a net loss for the first quarter of 2024 when the biotechnology company’s revenues declined sharply. Q1 loss was $1.18 billion or $3.07, compared to a profit of $79 million or $0.19 per share in the prior-year period.
The bottom line was negatively impacted by a 91% fall in revenues to $167 million, reflecting a marked decline in product revenues. The management reaffirmed the full-year expected revenue of around $4 billion from its respiratory franchise, and now expects about $0.3 billion in net sales in the first half of the year, reflecting the seasonality of the respiratory business.
“With 10 late-stage programs, and additional new programs advancing toward pivotal studies, we continue to expect numerous product milestones this year across our vaccines and therapeutics portfolio. This is the start of a banner year for our vaccine platform as we continue to advance mRNA medicines for patients. This is just the beginning,” said Moderna’s CEO Stéphane Bancel.
Prior Performance
Listen to the conference calls as they happen. Don't miss a beat! With AlphaStreet Intelligence, you can listen to live calls and interviews as they happen, so you never have to worry about missing out on important information.
Most Popular
After a weak first half, will NIKE (NKE) hit the recovery path this year?
After a prolonged slowdown, NIKE, Inc. (NYSE: NKE) is working on a turnaround plan to regain the brand’s strength. In recent years, the sneaker giant’s overall performance has not been
Important takeaways from Paychex’s (PAYX) Q2 2025 earnings report
Paychex Inc. (NASDAQ: PAYX), a leading provider of human resources and payroll services, reported better-than-expected revenue and profit for the second quarter of fiscal 2025, sending the stock higher soon
Lamb Weston’s (LW) challenges may not end soon, a few points to note
Shares of Lamb Weston Holdings, Inc. (NYSE: LW) turned red in mid-day trade on Friday. The stock has dropped 19% in the past one month. The company delivered disappointing results
